IN THE CLAIMS

Please amend claims 1-3 and add new claims 5-12 as follows:

- (Currently amended) A method for treating a host infected with a lentivirus comprising exposing said host to a lentivirus vector and a biologically acceptable carrier, excipient and diluent, wherein the lentivirus vector has an intact 5' lentivirus LTR.
- (Currently amended) The method of claim 1, wherein said vector has an intact 5' LTR
 a packaging signal sequence.
- 3. (Currently amended) The method of claim 1, wherein said lentivirus of the host infection is human immunodeficiency virus (HIV).



- 4. (Original) The method of claim 3, wherein said HIV is HIV-1.
- 5. (New) The method of claim 1, wherein the lentivirus vector is derived from HIV.
- 6. (New) The method of claim 5, wherein the HIV is HIV-1.
- 7. (New) The method of claim 1, wherein the treating comprises inhibiting lentiviral replication.
- 8. (New) The method of claim 1, wherein the lentivirus vector has 124 base pairs of nef sequences upstream of the 3' LTR replaced with a polylinker.
- 9. (New) The method of claim 2, wherein the packaging signal sequence comprises the leader sequence downstream of the LTR and until the beginning of the gag gene.
- 10. (New) The method of claim 1, wherein the lentivirus vector includes the rev response element.

The state of the s

- 11. (New) The method of claim 1, wherein the lentivirus vector contains a transgene.
- 12. (New) The method of claim 1, wherein the lentivirus vector lacks a transgene.